Multicenter Retrospective Study of Secukinumab Drug Survival in Psoriasis Patients in a Daily Practice Setting: A Long-Term Experience in Spain

INTRODUCTION: There is limited and conflicting evidence over the real-world drug survival of secukinumab (SEC) in patients with psoriasis, especially in the long term. Our objective was to analyze the short- and long-term survival of SEC (S-SEC) and its predictive factors for the treatment of psoria...

Descripción completa

Detalles Bibliográficos
Autores principales: Daudén, Esteban, de Lima, Glauber Pacelli Gomes, Armesto, Susana, Herrera-Acosta, Enrique, Vidal, David, Villarasa, Eva, Rivera, Raquel, de la Cueva, Pablo, Martorell, Antonio, Ballesca, Ferran, Belinchón, Isabel, Carretero, Gregorio, Rodríguez, Lourdes, Romero-Maté, Alberto, Pujol-Montcusí, Josep, Salgado, Laura, Sahuquillo-Torralba, Antonio, Coto-Segura, Pablo, Baniandrés, Ofelia, Feltes, Rosa, Alsina, Mercé, Llamas-Velasco, Mar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611164/
https://www.ncbi.nlm.nih.gov/pubmed/34561788
http://dx.doi.org/10.1007/s13555-021-00606-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611164/
https://www.ncbi.nlm.nih.gov/pubmed/34561788
http://dx.doi.org/10.1007/s13555-021-00606-9

Ejemplares similares